Reviva Pharmaceuticals Q3 EPS $(0.44) Misses $(0.37) Estimate
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals (NASDAQ:RVPH) reported a Q3 EPS loss of $(0.44), missing the consensus estimate of $(0.37) by 18.92%. This represents a significant increase in losses compared to the $(0.18) per share from the same quarter last year, indicating a 144.44% decrease in earnings.
November 14, 2023 | 9:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Reviva Pharmaceuticals reported a larger than expected quarterly loss of $(0.44) per share compared to the $(0.37) estimate, a 144.44% increase in losses from the previous year.
The reported earnings miss is likely to negatively impact investor sentiment in the short term, as the loss per share was significantly higher than expected and represents a substantial increase from the previous year's losses.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100